Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo
Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals (NASDAQ:IONS) today announced the presentation of a poster summarizing results from the completed Phase 1/2 clinical study of AKCEA-APOCIII-LRx at the American College of Cardiology (ACC) Annual Scientific Session & Expo on March 10, 2018, in Orlando, Florida. As quoted in the press release: “We are pleased to …
Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals (NASDAQ:IONS) today announced the presentation of a poster summarizing results from the completed Phase 1/2 clinical study of AKCEA-APOCIII-LRx at the American College of Cardiology (ACC) Annual Scientific Session & Expo on March 10, 2018, in Orlando, Florida.
As quoted in the press release:
“We are pleased to share the outcomes of this AKCEA-APOCIII-LRx study with the ACC community. The data showing significant and sustained reductions of multiple parameters, including ApoC-III and triglyceride levels, underscore the important regulatory role ApoC-III protein plays in controlling lipid levels in blood, and the potentially broad implications that reducing ApoC-III levels could have for cardiovascular health. We look forward to seeing the results from our AKCEA-APOCIII-LRx Phase 2 study in 2019,” said Dr. Louis O’Dea, chief medical officer at Akcea Therapeutics.